Janssen to Focus on Retinal Diseases with Multi-part MeiraGTx Deal

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)

Published: 9 Feb-2019

DOI: 10.3833/pdr.v2019.i2.2404     ISSN: 1756-7874

Section: Research & Development



Less than a year after its US$75 M initial public offering, UK based MeiraGTx has entered into a multi-part collaboration, option and licence agreement with Janssen Pharmaceuticals for the development of gene therapies to treat inherited retinal diseases (IRDs)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details